Skip to main content
Premium Trial:

Request an Annual Quote

Mixed Bag

Using genetic testing before prescribing blood thinners has shown mixed results, NPR's Shots blog says. The blood thinner Plavix does carry a warning saying that people whose genes show they are a slow metabolizer of the drug may not get a benefit from taking it, but doctors aren't sure if they should test patients and, if they do, they don't know what to do if a patient is a slow metabolizer. It gets murkier, the Shots blog adds, as a study from the makers of Plavix in the New England Journal of Medicine says that the drug works the same in people, despite what their genes say, though two studies in the Lancet support genetic testing. In addition, the Shots blog points out, Plavix is about to go generic and "pressure will build to save money."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.